Could be brodalumab, ixekizumab, secukinamab. All moving ahead in Phase 3, each could be looking for approval in the next couple of years, possibly. Apparently there are subsets of IL-17 so one or two of these might work better than the others.

The biochemistry of interleukins and there role in human diseases and inflammation have come to light over the past five years. Ustekinumab (IL-12 and IL-23 inhibition) is already approved for psoriasis and it looks quite effective. BTW, IL-23 seems to have synergistic effect on the activity of IL-17, so it's possible that IL-17 is THE one to inhibit for psoriasis, (but this obviously needs to be determined). IL-17 may also have a role in the inflammation associated with the production of amyloid protein that may cause neuro-tangles in the brains of Alzheimer sufferers in susceptible individuals.

It should be understood though that everyone has IL-17 activity but only susceptible individuals manifest diseases such as psoriasis, arthritis, Alzheimers, etc because of the biochemical activity of IL-17 (and who know what else).